Mitomycin Rx

Select the drug indication to add to your list

Mitomycin

Colorectal and other GI cancers
Pancreatic, thyroid, and other endocrine cancers
Only 4 drugs may be compared at once

Generic Name and Formulations:

Mitomycin 5mg/vial, 20mg/vial, 40mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol.

Select therapeutic use:

Indications for Mitomycin:

Disseminated adenocarcinoma of the stomach.

Adult:

Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments.

Children:

Not recommended.

Contraindications:

Thrombocytopenia. Coagulation disorders. Bleeding tendencies.

Warnings/Precautions:

Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with vinca alkaloids, other chemotherapy.

Pharmacological Class:

Cytotoxic antibiotic.

Adverse Reactions:

Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting.

Note:

Formerly known under the brand names Mitozytrex, Mutamycin.

How Supplied:

Contact supplier.

Indications for Mitomycin:

Disseminated adenocarcinoma of the pancreas.

Adult:

Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments.

Children:

Not recommended.

Contraindications:

Thrombocytopenia. Coagulation disorders. Bleeding tendencies.

Warnings/Precautions:

Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with vinca alkaloids, other chemotherapy.

Pharmacological Class:

Cytotoxic antibiotic.

Adverse Reactions:

Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting.

Note:

Formerly known under the brand names Mitozytrex, Mutamycin.

How Supplied:

Contact supplier.